Diabetes & Metabolism Journal

Original Articles

Complications
Impact of Hyperglycemia on Complication and Mortality after Transarterial Chemoembolization for Hepatocellular Carcinoma: Sun Joon Moon, Chang Ho Ahn, Yun Bin Lee, Young Min Cho; Diabetes Metab J. 2024;48(2):302-311. Published online January 3, 2024; DOI: https://doi.org/10.4093/dmj.2022.0255

1,538 View
191 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Current guidelines regarding periprocedural glycemic control to prevent complications after nonsurgical invasive procedures are insufficient. Transarterial chemoembolization (TACE) is a widely used treatment for unresectable hepatocellular carcinoma. We aimed to investigate the association between diabetes mellitus (DM) per se and the degree of hyperglycemia with postprocedural complications after TACE.
Methods
A total of 22,159 TACE procedures performed at Seoul National University Hospital from 2005 to 2018 were retrospectively analyzed. The associations between DM, preprocedural glycosylated hemoglobin (HbA1c), and periprocedural average glucose with postprocedural adverse outcomes were evaluated. The primary outcome was occurrence of postprocedural bacteremia. Secondary outcomes were acute kidney injury (AKI), delayed discharge and death within 14 days. Periprocedural glucose was averaged over 3 days: the day of, before, and after the TACE procedures. Propensity score matching was applied for procedures between patients with or without DM.
Results
Periprocedural average glucose was significantly associated with bacteremia (adjusted odds ratio per 50 mg/dL of glucose, 1.233; 95% confidence interval, 1.071 to 1.420; P=0.004), AKI, delayed discharge, and death within 14 days. DM per se was only associated with bacteremia and AKI. Preprocedural HbA1c was associated with delayed discharge. Average glucose levels above 202 and 181 mg/dL were associated with a significantly higher risk of bacteremia and AKI, respectively, than glucose levels of 126 mg/dL or lower.
Conclusion
Periprocedural average glucose, but not HbA1c, was associated with adverse outcomes after TACE, which is a nonsurgical invasive procedure. This suggests the importance of periprocedural glycemic control to reduce postprocedural complications.

Citations

Citations to this article as recorded by

Serum CYFRA 21-1 and CK19-2G2 as Predictive Biomarkers of Response to Transarterial Chemoembolization in Hepatitis C–related Hepatocellular Carcinoma Among Egyptians: A Prospective Study
Mohamed Y. Taher, Ehab Hassouna, Abeer El Hadidi, Omar El-aassar, Mohamed Fathy Bakosh, Mohamed Said Shater
Journal of Clinical and Experimental Hepatology.2025; 15(1): 102405. CrossRef

Metabolic Risk/Epidemiology
Higher Muscle Mass Protects Women with Gestational Diabetes Mellitus from Progression to Type 2 Diabetes Mellitus: Yujin Shin, Joon Ho Moon, Tae Jung Oh, Chang Ho Ahn, Jae Hoon Moon, Sung Hee Choi, Hak Chul Jang; Diabetes Metab J. 2022;46(6):890-900. Published online April 28, 2022; DOI: https://doi.org/10.4093/dmj.2021.0334

5,743 View
238 Download
4 Web of Science
4 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
We evaluated whether postpartum muscle mass affects the risk of type 2 diabetes mellitus (T2DM) in Korean women with gestational diabetes mellitus (GDM).
Methods
A total of 305 women with GDM (mean age, 34.9 years) was prospectively evaluated for incident prediabetes and T2DM from 2 months after delivery and annually thereafter. Appendicular skeletal muscle mass (ASM) was assessed with bioelectrical impedance analysis at the initial postpartum visit, and ASM, either divided by body mass index (BMI) or squared height, and the absolute ASM were used as muscle mass indices. The risk of incident prediabetes and T2DM was assessed according to tertiles of these indices using a logistic regression model.
Results
After a mean follow-up duration of 3.3 years, the highest ASM/BMI tertile group had a 61% lower risk of incident prediabetes and T2DM compared to the lowest tertile group, and this remained significant after we adjusted for covariates (adjusted odds ratio, 0.37; 95% confidence interval [CI], 0.15 to 0.92; P=0.032). Equivalent findings were observed in normal weight women (BMI <23 kg/m²), but this association was not significant for overweight women (BMI ≥23 kg/m²). Absolute ASM or ASM/height² was not associated with the risk of postpartum T2DM.
Conclusion
A higher muscle mass, as defined by the ASM/BMI index, was associated with a lower risk of postpartum prediabetes and T2DM in Korean women with GDM.

Citations

Citations to this article as recorded by

Low muscle mass index is associated with type 2 diabetes risk in a Latin-American population: a cross-sectional study
Rosario Suárez, Celina Andrade, Estefania Bautista-Valarezo, Yoredy Sarmiento-Andrade, Andri Matos, Oliver Jimenez, Martha Montalvan, Sebastián Chapela
Frontiers in Nutrition.2024;[Epub] CrossRef
More appendicular lean mass relative to body mass index is associated with lower incident diabetes in middle-aged adults in the CARDIA study
Melanie S. Haines, Aaron Leong, Bianca C. Porneala, Victor W. Zhong, Cora E. Lewis, Pamela J. Schreiner, Karen K. Miller, James B. Meigs, Mercedes R. Carnethon
Nutrition, Metabolism and Cardiovascular Diseases.2023; 33(1): 105. CrossRef
The Association of the Triglyceride and Muscle to Fat Ratio During Early Pregnancy with the Development of Gestational Diabetes Mellitus
Fang Wang, Yuan-Yuan Bao, Kang Yu
Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 3187. CrossRef
Correlation of body composition in early pregnancy on gestational diabetes mellitus under different body weights before pregnancy
Li Xintong, Xu Dongmei, Zhang Li, Cao Ruimin, Hao Yide, Cui Lingling, Chen Tingting, Guo Yingying, Li Jiaxin
Frontiers in Endocrinology.2022;[Epub] CrossRef

Drug/Regimen
Efficacy and Safety of Self-Titration Algorithms of Insulin Glargine 300 units/mL in Individuals with Uncontrolled Type 2 Diabetes Mellitus (The Korean TITRATION Study): A Randomized Controlled Trial: Jae Hyun Bae, Chang Ho Ahn, Ye Seul Yang, Sun Joon Moon, Soo Heon Kwak, Hye Seung Jung, Kyong Soo Park, Young Min Cho; Diabetes Metab J. 2022;46(1):71-80. Published online June 16, 2021; DOI: https://doi.org/10.4093/dmj.2020.0274

10,106 View
463 Download
2 Web of Science
4 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

Background
To compare the efficacy and safety of two insulin self-titration algorithms, Implementing New Strategies with Insulin Glargine for Hyperglycemia Treatment (INSIGHT) and EDITION, for insulin glargine 300 units/mL (Gla-300) in Korean individuals with uncontrolled type 2 diabetes mellitus (T2DM).
Methods
In a 12-week, randomized, open-label trial, individuals with uncontrolled T2DM requiring basal insulin were randomized to either the INSIGHT (adjusted by 1 unit/day) or EDITION (adjusted by 3 units/week) algorithm to achieve a fasting self-monitoring of blood glucose (SMBG) in the range of 4.4 to 5.6 mmol/L. The primary outcome was the proportion of individuals achieving a fasting SMBG ≤5.6 mmol/L without noct urnal hypoglycemia at week 12.
Results
Of 129 individuals (age, 64.1±9.5 years; 66 [51.2%] women), 65 and 64 were randomized to the INSIGHT and EDITION algorithms, respectively. The primary outcome of achievement was comparable between the two groups (24.6% vs. 23.4%, P=0.876). Compared with the EDITION group, the INSIGHT group had a greater reduction in 7-point SMBG but a similar decrease in fasting plasma glucose and glycosylated hemoglobin. The increment of total daily insulin dose was significantly higher in the INSIGHT group than in the EDITION group (between-group difference: 5.8±2.7 units/day, P=0.033). However, body weight was significantly increased only in the EDITION group (0.6±2.4 kg, P=0.038). There was no difference in the occurrence of hypoglycemia between the two groups. Patient satisfaction was significantly increased in the INSIGHT group (P=0.014).
Conclusion
The self-titration of Gla-300 using the INSIGHT algorithm was effective and safe compared with that using the EDITION algorithm in Korean individuals with uncontrolled T2DM (ClinicalTrials.gov number: NCT03406663).

Citations

Citations to this article as recorded by

Time for Using Machine Learning for Dose Guidance in Titration of People With Type 2 Diabetes? A Systematic Review of Basal Insulin Dose Guidance
Camilla Heisel Nyholm Thomsen, Stine Hangaard, Thomas Kronborg, Peter Vestergaard, Ole Hejlesen, Morten Hasselstrøm Jensen
Journal of Diabetes Science and Technology.2024; 18(5): 1185. CrossRef
Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: A network meta‐analysis of randomized clinical trials
Hazem Ayesh, Sajida Suhail, Suhail Ayesh, Kevin Niswender
Diabetes, Obesity and Metabolism.2024; 26(9): 3801. CrossRef
Basal insulin titration algorithms in patients with type 2 diabetes: the simplest is the best (?)
V.I. Katerenchuk
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2023; 19(1): 72. CrossRef
Issues of insulin therapy for type 2 diabetes and ways to solve them
V.I. Katerenchuk, A.V. Katerenchuk
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2023; 19(3): 240. CrossRef

Response

Response: Premeal Consumption of a Protein-Enriched, Dietary Fiber-Fortified Bar Decreases Total Energy Intake in Healthy Individuals (Diabetes Metab J 2019;43:879–92): Chang Ho Ahn, Jae Hyun Bae, Young Min Cho; Diabetes Metab J. 2020;44(1):207-208. Published online February 21, 2020; DOI: https://doi.org/10.4093/dmj.2020.0026; [Original]

3,692 View
56 Download

PDF PubReader

Original Article

Obesity and Metabolic Syndrome
Premeal Consumption of a Protein-Enriched, Dietary Fiber-Fortified Bar Decreases Total Energy Intake in Healthy Individuals: Chang Ho Ahn, Jae Hyun Bae, Young Min Cho; Diabetes Metab J. 2019;43(6):879-892. Published online June 25, 2019; DOI: https://doi.org/10.4093/dmj.2018.0202

6,098 View
94 Download
4 Web of Science
6 Crossref

Abstract PDF Supplementary Material PubReader

Background

A premeal load of protein can increase satiety and reduce energy intake. Dietary fiber also conveys metabolic benefits by modulating energy intake. We made a protein-enriched, dietary fiber-fortified bar (PFB) and aimed to investigate its effects on food intake and gut hormone secretion in healthy individuals.

Methods

Twenty subjects with normal glucose tolerance were enrolled. On three separate visits, the subjects received, in a randomized order, one of the following: a PFB containing 73 kcal with 10.7 g of protein and 12.7 g of dietary fiber; a usual bar (UB) containing the same calories as the PFB but only 0.9 g of protein and no dietary fiber; or water (control). After 15 minutes, the subjects had ad libitum intake of a test meal. Food consumption, appetite, and plasma gut hormone levels were measured.

Results

Total energy intake, including the bar and the test meal, was significantly reduced with the PFB preload compared to the water (904.4±534.9 kcal vs. 1,075.0±508.0 kcal, P=0.016). With the UB preload, only the intake of the test meal was reduced (P=0.044) but not the total energy intake (P=0.471) than the water. Fullness was also significantly increased after the PFB. In addition, postprandial glucose levels decreased and glucagon-like peptide-1 levels increased with the PFB compared with both the UB and water.

Conclusion

In healthy individuals, a premeal supplementation of PFB reduced total energy intake and decreased postprandial glucose excursion. This finding necessitates long-term studies regarding clinical use in obesity.

Citations

Citations to this article as recorded by

Citrus pectin protects mice from burn injury by modulating intestinal microbiota, GLP-1 secretion and immune response
Ji-Wei Hao, Hong-Sheng Liu, Ling-Ying Liu, Qing-Hong Zhang
International Immunopharmacology.2024; 131: 111912. CrossRef
Effect of Two Different Meal Compositions on 1-hour Plasma Ghrelin Levels in Young Men
Brinnell Annette Caszo, Sangeetha Shyam, Purushotham Krishnappa, Justin Vijay Gnanou
Malaysian Journal of Medicine and Health Sciences.2023; 19(5): 185. CrossRef
Intake of Fibre-Associated Foods and Texture Preferences in Relation to Weight Status Among 9–12 Years Old Children in 6 European Countries
Marlies Hörmann-Wallner, Raphaela Krause, Begoña Alfaro, Hannah Jilani, Monica Laureati, Valérie L. Almli, Mari Sandell, Pernilla Sandvik, Gertrude G. Zeinstra, Lisa Methven
Frontiers in Nutrition.2021;[Epub] CrossRef
Response: Premeal Consumption of a Protein-Enriched, Dietary Fiber-Fortified Bar Decreases Total Energy Intake in Healthy Individuals (Diabetes Metab J 2019;43:879–92)
Chang Ho Ahn, Jae Hyun Bae, Young Min Cho
Diabetes & Metabolism Journal.2020; 44(1): 207. CrossRef
Letter: Premeal Consumption of a Protein-Enriched, Dietary Fiber-Fortified Bar Decreases Total Energy Intake in Healthy Individuals (Diabetes Metab J 2019;43:879–92)
Mi-kyung Kim
Diabetes & Metabolism Journal.2020; 44(1): 203. CrossRef
Spent coffee (Coffea arabicaL.) grounds promote satiety and attenuate energy intake: A pilot study
Rocio Campos‐Vega, Andrea Arreguín‐Campos, Miguel A. Cruz‐Medrano, María Dolores Castillo Bilbao
Journal of Food Biochemistry.2020;[Epub] CrossRef

Response

Response: Normal Glucose Tolerance with a High 1-Hour Postload Plasma Glucose Level Exhibits Decreased β-Cell Function Similar to Impaired Glucose Tolerance (Diabetes Metab J 2015;39:147-53): Tae Jung Oh, Se Hee Min, Chang Ho Ahn, Eun Ky Kim, Soo Heon Kwak, Hye Seung Jung, Kyong Soo Park, Young Min Cho; Diabetes Metab J. 2015;39(3):270-271. Published online June 15, 2015; DOI: https://doi.org/10.4093/dmj.2015.39.3.270

3,663 View
35 Download
1 Crossref

PDF PubReader

Citations

Citations to this article as recorded by

Prevalence of Impaired Glucose Tolerance/Prediabetes in Local Adult Obese Population Presenting to A Tertiary Care Hospital
Niktash Khan Hadi, Muhammad Salman Aamir, Tahir Ghaffar, Sulaiman Khan, Siraj ul Islam, Shafiullah Khan, Nizamuddin ., Muhammad Ali
Pakistan Journal of Health Sciences.2023; : 84. CrossRef

Review

New Drugs for Treating Dyslipidemia: Beyond Statins: Chang Ho Ahn, Sung Hee Choi; Diabetes Metab J. 2015;39(2):87-94. Published online April 20, 2015; DOI: https://doi.org/10.4093/dmj.2015.39.2.87

6,056 View
84 Download
41 Web of Science
37 Crossref

Abstract PDF PubReader

Statins have been shown to be very effective and safe in numerous randomized clinical trials, and became the implacable first-line treatment against atherogenic dyslipidemia. However, even with optimal statin treatment, 60% to 80% of residual cardiovascular risk still exists. The patients with familial hypercholesterolemia which results in extremely high level of low density lipoprotein cholesterol (LDL-C) level and the patients who are intolerant or unresponsive to statins are the other hurdles of statin treatment. Recently, new classes of lipid-lowering drugs have been developed and some of them are available for the clinical practice. The pro-protein convertase subtilisin/kexintype 9 (PCSK9) inhibitor increases the expression of low density lipoprotein (LDL) receptor in hepatocytes by enhancing LDL receptor recycling. The microsomal triglyceride transport protein (MTP) inhibitor and antisense oligonucleotide against apolipoprotein B (ApoB) reduce the ApoB containing lipoprotein by blocking the hepatic very low density lipoprotein synthesis pathway. The apolipoprotein A1 (ApoA1) mimetics pursuing the beneficial effect of high density lipoprotein cholesterol and can reverse the course of atherosclerosis. ApoA1 mimetics had many controversial clinical data and need more validation in humans. The PCSK9 inhibitor recently showed promising results of significant LDL-C lowering in familial hypercholesterolemia (FH) patients from the long-term phase III trials. The MTP inhibitor and antisesnse oligonucleotide against ApoB were approved for the treatment of homozygous FH but still needs more consolidated evidences about hepatic safety such as hepatosteatosis. We would discuss the benefits and concerns of these new lipid-lowering drugs anticipating additional benefits beyond statin treatment.

Citations

Citations to this article as recorded by

Role of PCSK9 inhibitors in the management of dyslipidaemia
Tiny Nair
Indian Heart Journal.2024; 76: S44. CrossRef
Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?
Henriette Thau, Sebastian Neuber, Maximilian Y. Emmert, Timo Z. Nazari-Shafti
Cardiology and Therapy.2024; 13(1): 39. CrossRef
UHPLC Specific Method for Simultaneous Determination of Probable Impurities of Ezetimibeand Simvastatin in Combined Dosage Form
Anantha Lakshmi Vadivelu, Sathapathy Panduranga Vittal, Duvvuri Suryakala
Oriental Journal Of Chemistry.2024; 40(1): 228. CrossRef
PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes
Daniela Grejtakova, Iveta Boronova, Jarmila Bernasovska, Stefano Bellosta
Cardiovascular Drugs and Therapy.2024;[Epub] CrossRef
LC‐MS based metabolite profiling, in‐vitro antioxidant and in‐vivo antihyperlipidemic activity of Nigella sativa extract
Amit Kumar Shrivastava, Laxmi Shrestha, Buddhi Raj Pokhrel, Bishal Joshi, Gopal Lamichhane, Bojana Vidović, Niranjan Koirala
eFood.2023;[Epub] CrossRef
Development of New Genome Editing Tools for the Treatment of Hyperlipidemia
Giulio Preta
Cells.2023; 12(20): 2466. CrossRef
High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine
E. Reijnders, A. van der Laarse, J. W. Jukema, C. M. Cobbaert
Frontiers in Cardiovascular Medicine.2023;[Epub] CrossRef
Riesgo residual. Conclusiones
Ángel Cequier, José Luis Zamorano
Revista Española de Cardiología Suplementos.2023; 23: 25. CrossRef
Anti-hyperglycemic, anti-hyperlipidemic, and anti-inflammatory effect of the drug Guggulutiktaka ghrita on high-fat diet-induced obese rats
Samreen M. Sheik, Pugazhandhi Bakthavatchalam, Revathi P. Shenoy, Basavaraj S. Hadapad, Deepak Nayak M, Monalisa Biswas, Varashree Bolar Suryakanth
Journal of Ayurveda and Integrative Medicine.2022; 13(3): 100583. CrossRef
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi
Diabetes & Metabolism Journal.2022; 46(4): 517. CrossRef
A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
Kyuho Kim, Sung Hee Choi
Journal of Lipid and Atherosclerosis.2022; 11(3): 250. CrossRef
Tyramine exerts hypolipidemic and anti-obesity effects in vivo
Thamires Maria Fontenele Morais, Tiago Sousa Melo, Mariana Brito Dantas, Jamile Magalhães Ferreira, Daniel Freire de Sousa, Emanuel Paula Magalhães, Ramon Róseo Paula Pessoa Bezerra de Menezes, Otília Deusdênia Loiola Pessoa, Mariana Lima Feitosa, Francis
Brazilian Journal of Pharmaceutical Sciences.2022;[Epub] CrossRef
Statin adherence and risk of all-cause, cancer, and cardiovascular mortality among dyslipidemia patients: A time-dependent analysis
Young Ran Lee, Sarah Soyeon Oh, Sung-In Jang, Eun-Cheol Park
Nutrition, Metabolism and Cardiovascular Diseases.2020; 30(12): 2207. CrossRef
Efficient reabsorption of transintestinally excreted cholesterol is a strong determinant for cholesterol disposal in mice
Ivo P. van de Peppel, Anna Bertolini, Theo H. van Dijk, Albert K. Groen, Johan W. Jonker, Henkjan J. Verkade
Journal of Lipid Research.2019; 60(9): 1562. CrossRef
Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
Jah Yeon Choi, Jin Oh Na
Journal of Lipid and Atherosclerosis.2019; 8(2): 183. CrossRef
Effects of silymarin supplementation on blood lipids: A systematic review and meta‐analysis of clinical trials
Hamed Mohammadi, Amir Hadi, Arman Arab, Sajjad Moradi, Mohammad Hossein Rouhani
Phytotherapy Research.2019; 33(4): 871. CrossRef
Change in ALT levels after administration of HMG‐CoA reductase inhibitors to subjects with pretreatment levels three times the upper normal limit in clinical practice
Hyunah Kim, Hyeseon Lee, Tong Min Kim, So Jung Yang, Seo Yeon Baik, Seung‐Hwan Lee, Jae‐Hyoung Cho, Hyunyong Lee, Hyeon Woo Yim, In Young Choi, Kun‐Ho Yoon, Hun‐Sung Kim
Cardiovascular Therapeutics.2018;[Epub] CrossRef
Host-targeting therapies for hepatitis C virus infection: current developments and future applications
Emilie Crouchet, Florian Wrensch, Catherine Schuster, Mirjam B. Zeisel, Thomas F. Baumert
Therapeutic Advances in Gastroenterology.2018; 11: 175628481875948. CrossRef
New and Future Parenteral Therapies for the Management of Lipid Disorders
Roberto Garcia, Jaime Burkle
Archives of Medical Research.2018; 49(8): 538. CrossRef
NEW DRUGS FOR THE TREATMENT OF DYSLIPIDEMIA
Aleksandra Novaković, Marija Marinko, Ivan Stojanović, Dragoslav Nenezić, Predrag Milojević, Vladimir Kanjuh
Acta Medica Medianae.2018; 57(1): 54. CrossRef
Effects of diethylene glycol dibenzoate and Bisphenol A on the lipid metabolism of Danio rerio
Stefania Santangeli, Valentina Notarstefano, Francesca Maradonna, Elisabetta Giorgini, Giorgia Gioacchini, Isabel Forner-Piquer, Hamid R. Habibi, Oliana Carnevali
Science of The Total Environment.2018; 636: 641. CrossRef
Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment
Victoria A Serhiyenko, Alexandr A Serhiyenko
World Journal of Diabetes.2018; 9(1): 1. CrossRef
Krüppel-like factor 14, a coronary artery disease associated transcription factor, inhibits endothelial inflammation via NF-κB signaling pathway
Wenting Hu, Haocheng Lu, Jifeng Zhang, Yanbo Fan, Ziyi Chang, Wenying Liang, Huilun Wang, Tianqing Zhu, Minerva T. Garcia-Barrio, Daoquan Peng, Y. Eugene Chen, Yanhong Guo
Atherosclerosis.2018; 278: 39. CrossRef
Strategies for the use of nonstatin therapies
Angela Pirillo, Giuseppe D. Norata, Alberico L. Catapano
Current Opinion in Lipidology.2017; 28(6): 458. CrossRef
The efficacy advantage of evolocumab (AMG 145) dosed at 140 mg every 2 weeks versus 420 mg every 4 weeks in patients with hypercholesterolemia: Evidence from a meta-analysis
Xiao-Xiao He, Rong Zhang, Pei-Yuan Zuo, Yu-Wei Liu, Xiang-Nan Zha, Sheng-Shuai Shan, Cheng-Yun Liu
European Journal of Internal Medicine.2017; 38: 52. CrossRef
The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease
Carlota Recio, Francesco Maione, Asif J. Iqbal, Nicola Mascolo, Vincenzo De Feo
Frontiers in Pharmacology.2017;[Epub] CrossRef
Emerging biologic therapies for hypercholesterolaemia
Giacomo Pucci, Arrigo F Cicero, Claudio Borghi, Giuseppe Schillaci
Expert Opinion on Biological Therapy.2017; 17(9): 1077. CrossRef
ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic–therapeutic pathway in Italy
Michele Massimo Gulizia, Furio Colivicchi, Gualtiero Ricciardi, Simona Giampaoli, Aldo Pietro Maggioni, Maurizio Averna, Maria Stella Graziani, Ferruccio Ceriotti, Alessandro Mugelli, Francesco Rossi, Gerardo Medea, Damiano Parretti, Maurizio Giuseppe Abr
European Heart Journal Supplements.2017; 19(suppl_D): D3. CrossRef
Rev-erb regulation of cholesterologenesis
Sadichha Sitaula, Jinsong Zhang, Fernanda Ruiz, Thomas P. Burris
Biochemical Pharmacology.2017; 131: 68. CrossRef
Novel lipid modifying drugs to lower LDL cholesterol
Arjen J. Cupido, Laurens F. Reeskamp, John J.P. Kastelein
Current Opinion in Lipidology.2017; 28(4): 367. CrossRef
2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document
Massimo Volpe, Roberto Volpe, Giovanna Gallo, Vivianne Presta, Giuliano Tocci, Emanuela Folco, Andrea Peracino, Elena Tremoli, Bruno Trimarco
High Blood Pressure & Cardiovascular Prevention.2017; 24(3): 313. CrossRef
Sobetirome: the past, present and questions about the future
Jan Lammel Lindemann, Paul Webb
Expert Opinion on Therapeutic Targets.2016; 20(2): 145. CrossRef
Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes
Maritza J. Romero, Rudolf Lucas, Huijuan Dou, Supriya Sridhar, Istvan Czikora, Eby M. Mosieri, Ferenc G. Rick, Norman L. Block, Subbaramiah Sridhar, David Fulton, Neal L. Weintraub, Zsolt Bagi, Andrew V. Schally
Proceedings of the National Academy of Sciences.2016; 113(7): 1895. CrossRef
Recent trends in and new data on the epidemiology and prevention of non-communicable diseases
S. A. Boytsov
Terapevticheskii arkhiv.2016; 88(1): 4. CrossRef
Cellular Model of Atherogenesis Based on Pluripotent Vascular Wall Pericytes
Ekaterina A. Ivanova, Alexander N. Orekhov, Agnes L. Nishimura
Stem Cells International.2016;[Epub] CrossRef
Pre-treatment with simvastatin prevents the induction of diet-induced atherosclerosis in a rabbit model
Nikolaos Oikonomidis, Nikolaos Kavantzas, Laskarina-Maria Korou, Panagiotis Konstantopoulos, Vasilios Pergialiotis, Evangelos Misiakos, Ioannis Rizos, Christos Verikokos, Despina N. Perrea
Biomedical Reports.2016; 5(6): 667. CrossRef
Prevention of oxLDL uptake leads to decreased atherosclerosis in hematopoietic NPC1-deficient Ldlr−/− mice
Mike L.J. Jeurissen, Sofie M.A. Walenbergh, Tom Houben, Marion J.J. Gijbels, Jieyi Li, Tim Hendrikx, Yvonne Oligschlaeger, Patrick J. van Gorp, Christoph J. Binder, Marjo M.P.C. Donners, Ronit Shiri-Sverdlov
Atherosclerosis.2016; 255: 59. CrossRef

Original Article

Normal Glucose Tolerance with a High 1-Hour Postload Plasma Glucose Level Exhibits Decreased β-Cell Function Similar to Impaired Glucose Tolerance: Tae Jung Oh, Se Hee Min, Chang Ho Ahn, Eun Ky Kim, Soo Heon Kwak, Hye Seung Jung, Kyong Soo Park, Young Min Cho; Diabetes Metab J. 2015;39(2):147-153. Published online March 9, 2015; DOI: https://doi.org/10.4093/dmj.2015.39.2.147

4,846 View
49 Download
17 Web of Science
14 Crossref

Abstract PDF PubReader

Background

Subjects with normal glucose tolerance (NGT) who have a high 1-hour postload plasma glucose level (≥155 mg/dL; NGT 1 hour-high) have been shown to be at higher risk for type 2 diabetes than subjects with NGT 1 hour-low postload plasma glucose level (<155 mg/dL). We compared β-cell function in subjects with NGT 1 hour-high, NGT 1 hour-low, and impaired glucose tolerance (IGT).

Methods

We classified subjects into NGT 1 hour-low (n=149), NGT 1 hour-high (n=43), and IGT (n=52). The β-cell function was assessed based on insulinogenic index (IGI), oral disposition index (DI), and insulin secretion-sensitivity index-2 (ISSI-2).

Results

Insulin sensitivity was comparable between the subjects with NGT 1 hour-high and NGT 1 hour-low. The β-cell function with/without adjusting insulin sensitivity was significantly different among the three groups. The IGI (pmol/mmol) was 116.8±107.3 vs. 64.8±47.8 vs. 65.8±80.6 (P=0.141), oral DI was 3.5±4.2 vs. 1.8±1.4 vs. 1.8±3.1 (P<0.001), and ISSI-2 was 301.2±113.7 vs. 213.2±67.3 vs. 172.5±87.5 (P<0.001) in NGT 1 hour-low, NGT 1 hour-high, and IGT, respectively. Post hoc analyses revealed that oral DI and ISSI-2 were significantly different between NGT 1 hour-low and NGT 1 hour-high but comparable between NGT 1 hour-high and IGT.

Conclusion

Among Korean subjects with NGT, those who have a higher 1-hour postload glucose level have a compromised insulin-sensitivity adjusted β-cell function to a similar degree as IGT subjects.

Citations

Citations to this article as recorded by

Triglyceride-glucose index predicts type 2 diabetes mellitus more effectively than oral glucose tolerance test-derived insulin sensitivity and secretion markers
Min Jin Lee, Ji Hyun Bae, Ah Reum Khang, Dongwon Yi, Mi Sook Yun, Yang Ho Kang
Diabetes Research and Clinical Practice.2024; 210: 111640. CrossRef
Pathophysiological characteristics of subjects with intermediate hyperglycemia and type 2 diabetes identified by 1-hour plasma glucose during an oral glucose tolerance test
Chiara M.A. Cefalo, Alessia Riccio, Teresa Vanessa Fiorentino, Elena Succurro, Gaia Chiara Mannino, Maria Perticone, Angela Sciacqua, Francesco Andreozzi, Giorgio Sesti
Diabetes Research and Clinical Practice.2024; : 111856. CrossRef
Pancreatic fat accumulation is associated with decreased β‐cell function and deterioration in glucose tolerance in Korean adults
Sang Ouk Chin, You‐Cheol Hwang, In‐Jin Cho, In‐Kyung Jeong, Kyu Jeung Ahn, Ho Yeon Chung
Diabetes/Metabolism Research and Reviews.2021;[Epub] CrossRef
Indirect insulin resistance detection: Current clinical trends and laboratory limitations
Sylwia Placzkowska, Lilla Pawlik-Sobecka, Izabela Kokot, Agnieszka Piwowar
Biomedical Papers.2019; 163(3): 187. CrossRef
Clinical Implications of Using Post-Challenge Plasma Glucose Levels for Early Diagnosis of Type 2 Diabetes Mellitus in Older Individuals
Kyong Hye Joung, Sang Hyun Ju, Ji Min Kim, Sorim Choung, Jae Min Lee, Kang Seo Park, Hyun Jin Kim, Bon Jeong Ku
Diabetes & Metabolism Journal.2018; 42(2): 147. CrossRef
The 1-h post-load plasma glucose as a novel biomarker for diagnosing dysglycemia
Ram Jagannathan, Martin Buysschaert, José Luis Medina, Karin Katz, Sarah Musleh, Brenda Dorcely, Michael Bergman
Acta Diabetologica.2018; 55(6): 519. CrossRef
Elevated 1‐hour post‐load plasma glucose identifies obese youth with abnormal glucose metabolism and an unfavourable inflammatory profile
Anastasios Serbis, Vasileios Giapros, Anna Challa, Nikolaos Chaliasos, Ekaterini Siomou
Clinical Endocrinology.2018; 89(6): 757. CrossRef
One‐hour postload plasma glucose concentration in people with normal glucose homeostasis predicts future diabetes mellitus: a 12‐year community‐based cohort study
Tae Jung Oh, Soo Lim, Kyoung Min Kim, Jae Hoon Moon, Sung Hee Choi, Young Min Cho, Kyong Soo Park, HakChul Jang, Nam H. Cho
Clinical Endocrinology.2017; 86(4): 513. CrossRef
An elevated 1-h post- load glucose level during the oral glucose tolerance test detects prediabetes
Martin Buysschaert, Michael Bergman, Donald Yanogo, Ram Jagannathan, Benoit Buysschaert, Vanessa Preumont
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2017; 11(2): 137. CrossRef
Delayed insulin secretion response during an OGTT is associated with an increased risk for incidence of diabetes in NGT subjects
Yun Sun, Junfeng Han, Ziwei Lin, Lige Song, Chen Wang, Weiping Jia
Journal of Diabetes and its Complications.2016; 30(8): 1537. CrossRef
Postprandial Hyperglycemia
Tae Jung Oh
The Journal of Korean Diabetes.2016; 17(4): 233. CrossRef
β-Cell Function and Insulin Sensitivity in Normal Glucose-Tolerant Subjects Stratified by 1-Hour Plasma Glucose Values
Miranda M. Priya, Anandakumar Amutha, T.A. Pramodkumar, Harish Ranjani, Saravanan Jebarani, Kuppan Gokulakrishnan, Rajendra Pradeepa, Ranjit Unnikrishnan, Ranjit Mohan Anjana, Viswanathan Mohan
Diabetes Technology & Therapeutics.2016; 18(1): 29. CrossRef
Response: Normal Glucose Tolerance with a High 1-Hour Postload Plasma Glucose Level Exhibits Decreased β-Cell Function Similar to Impaired Glucose Tolerance (Diabetes Metab J2015;39:147-53)
Tae Jung Oh, Se Hee Min, Chang Ho Ahn, Eun Ky Kim, Soo Heon Kwak, Hye Seung Jung, Kyong Soo Park, Young Min Cho
Diabetes & Metabolism Journal.2015; 39(3): 270. CrossRef
Letter: Normal Glucose Tolerance with a High 1-Hour Postload Plasma Glucose Level Exhibits Decreased β-Cell Function Similar to Impaired Glucose Tolerance (Diabetes Metab J2015;39:147-53)
Hee Kyung Kim
Diabetes & Metabolism Journal.2015; 39(3): 268. CrossRef

First
Prev
Page of 1
Next
Last

Search